Catalent (NYSE:CTLT) Coverage Initiated by Analysts at StockNews.com

Research analysts at StockNews.com started coverage on shares of Catalent (NYSE:CTLT) in a research note issued on Monday. The brokerage set a “hold” rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Robert W. Baird reissued a “neutral” rating and issued a $63.50 price target on shares of Catalent in a research note on Tuesday, September 24th. Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Eight analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $63.40.

Catalent Price Performance

CTLT stock opened at $63.48 on Monday. Catalent has a 1 year low of $41.15 and a 1 year high of $63.50. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. The stock has a market cap of $11.52 billion, a price-to-earnings ratio of -28.09, a P/E/G ratio of 2.69 and a beta of 1.15. The company has a 50 day simple moving average of $62.24 and a 200 day simple moving average of $60.47.

Catalent (NYSE:CTLT) last posted its earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.06 billion. During the same quarter in the prior year, the business posted ($0.10) earnings per share. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. Research analysts anticipate that Catalent will post 0.78 EPS for the current fiscal year.

Insider Activity

In other news, Director Michelle R. Ryan sold 2,800 shares of the business’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the sale, the director now directly owns 10,835 shares of the company’s stock, valued at $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.31% of the stock is currently owned by company insiders.

Institutional Trading of Catalent

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Brooklyn Investment Group bought a new position in Catalent in the 3rd quarter valued at $31,000. Sentry Investment Management LLC bought a new position in Catalent during the third quarter valued at about $53,000. Thurston Springer Miller Herd & Titak Inc. increased its holdings in Catalent by 57.5% during the third quarter. Thurston Springer Miller Herd & Titak Inc. now owns 1,181 shares of the company’s stock worth $72,000 after buying an additional 431 shares during the last quarter. Intact Investment Management Inc. bought a new stake in Catalent in the third quarter worth about $73,000. Finally, GAMMA Investing LLC boosted its stake in Catalent by 26.9% in the third quarter. GAMMA Investing LLC now owns 1,310 shares of the company’s stock valued at $79,000 after acquiring an additional 278 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.